STAT+: Pharmalittle: Moderna and NIH clash over Covid-19 vaccine patent; Biogen probes Alzheimer’s patient death

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a challenging sojourn that has taken us away, albeit briefly, from the Pharmalot campus. We are, in fact, enjoying getting out and about again. Meanwhile, this marks the middle of the week, which means we have also managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few tidbits to help you on your own journey. Have a grand day, and drop us a line if you hear something saucy. …

Moderna (MRNA) and the National Institutes of Health are in a bitter dispute over who deserves credit for inventing the central component of the company’s Covid-19 vaccine, a conflict that has broad implications for the vaccine’s long-term distribution and billions of dollars in future profits, The New York Times writes. The vaccine grew out of a four-year collaboration between Moderna and the NIH, and the agency says three scientists at its Vaccine Research Center worked with Moderna scientists to design the genetic sequence that prompts the vaccine to produce an immune response, and should be named on the “principal patent application.” Moderna disagrees.

Continue to STAT+ to read the full story…